z-logo
open-access-imgOpen Access
Design, Sustainable Synthesis, Characterization, Antimicrobial Evaluation and in silico ADMET Prediction of New Functionalized Imidazolium Based Ionic Liquids
Author(s) -
Anas R. Al Johani,
Saud M. Almutairi,
Wael S. ElSayed,
Pramod K. Sahu,
Praveen Kumar Sahu,
Mouslim Messali
Publication year - 2020
Publication title -
asian journal of chemistry/asian journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.145
H-Index - 34
eISSN - 0975-427X
pISSN - 0970-7077
DOI - 10.14233/ajchem.2020.22747
Subject(s) - ionic liquid , chemistry , antimicrobial , in silico , alkyl , moiety , bioavailability , minimum inhibitory concentration , in vivo , combinatorial chemistry , nuclear chemistry , organic chemistry , biochemistry , pharmacology , microbiology and biotechnology , medicine , gene , catalysis , biology
A series of sixteen new ionic liquids (ILs) bearing imidazolium moiety were designed and synthesizedunder sustainable and green conditions which were confirmed by analytical and spectral techniquesusing 1H- & 13C-NMR, FT-IR, mass and elemental analysis. A panel of clinically isolated strains wasused for in vitro inhibitory antimicrobial activities screening of synthesized ionic liquids. The resultsof antimicrobial assay showed that some of synthesized ionic liquids showed moderate to good activity.Among these ILs, ionic liquids 3, 4 and 5 (bearing alkyl chain with a phenyl group) significantlyinhibited cell growth of strains. In this regard, these ionic liquids considered as promising antibacterialagents when compared with standard antibiotics. By encouraging in vitro antimicrobial screening, insilico ADMET evaluation has been performed and found excellent pharmacokinetic, bioavailabilityand toxicity profiles. Synthesized ionic liquids has found to be safe and non-toxic according to calculatedin vivo computed LD50 values (2.49-2.80 mg/kg) for rat acute toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here